Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesGlycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical reviewIn vitro and in vivo modifications of recombinant and human IgG antibodiesDifferent glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.Growth of Viridans streptococci on human serum alpha1-acid glycoprotein.LC-MS/MS peptide mapping with automated data processing for routine profiling of N-glycans in immunoglobulins.Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Advances in animal cell recombinant protein production: GS-NS0 expression system.Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug developmentPro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cellsAntibody therapeutics: isotype and glycoform selection.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Engineering mammalian cells in bioprocessing - current achievements and future perspectives.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.IgG-Fc glycoengineering in non-mammalian expression hostsExpression of recombinant antibodies.Glycosylation: impact, control and improvement during therapeutic protein production.Diversity in host clone performance within a Chinese hamster ovary cell line.Impact of cell culture on recombinant monoclonal antibody product heterogeneity.Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPOCharacterization of the proteases involved in the N-terminal clipping of glucagon-like-peptide-1-antibody fusion proteins.Overview of protein expression by mammalian cells.Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in PlantsModulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer TherapyMetabolic control of recombinant protein N-glycan processing in NS0 and CHO cells.Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure.High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.Metabolic engineering II. Eukaryotic systems.Optimization of humanized IgGs in glycoengineered Pichia pastoris.Purification of chimeric heavy chain monoclonal antibody EG2-hFc using hydrophobic interaction membrane chromatography: an alternative to protein-A affinity chromatography.Complement and cellular cytotoxicity in antibody therapy of cancerFucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
P2860
Q21131216-DA71FB75-192A-438B-AA84-04FE7FA3B3ADQ26782025-ED986223-2D2F-4463-8AFD-958301A40437Q26859713-ACF636AF-6D88-436A-A9B1-5028D4CA55BDQ30428210-E11D16D7-3FCA-41AE-BA7C-8E1922E3D802Q30732375-B2A21F8D-F1E5-4A6C-ABEF-EE369288EC18Q30784999-6F5A5ED1-C206-4A57-9764-50B819AD533BQ30835165-23B9DFE1-4627-4F7F-A4D8-90AF422C13FAQ31214737-DA23BEDD-69CE-40E8-95DA-32FE79D86F49Q34323394-4A021EAD-A953-43A4-9E63-0C48CE5249A1Q34574834-5E4ADDCC-E9C2-48B3-9E74-42F977C464A4Q34878044-3DFA308A-7AAE-47C3-9C4B-161F6B09F3C9Q35105725-8D3847BC-2859-419F-B26A-7413E153AB93Q35873009-2BCA648F-3F33-4070-A539-B90E33029EF7Q36216376-500CB21F-B347-43D8-8809-8BEE1BF1134FQ36254504-EE1BB685-9320-4DD9-ABBF-C71A5AC2A811Q36922260-6C8C6D11-A17C-4758-A4B3-1C3B357D4DECQ37364355-0C5D2E34-3EBA-4CB7-A592-B90A96B75F87Q37730868-8CE0C5E9-6A2A-467D-84CE-5CA77F2E96EEQ37998314-AF87B8E0-AA00-40CB-B2FD-44ACCD689CE1Q38013479-31C0A0BB-74AB-4DE2-8E69-4A6AC891BBBFQ38126016-F0346DF9-D00B-4A93-AD2F-519563E1F3B6Q38126913-54519CBB-233F-4FD7-B2A7-FCD10F8A21C7Q38881563-D500A2CC-9908-4589-8A00-E4897D0D7AD6Q38907094-CE223A00-62B7-4B87-8099-03C36AC24700Q39439938-A7630E1D-F371-4CA7-AD43-105C340BD207Q39594082-E4EDDBD3-8937-4174-89E6-7F810B410A98Q39989577-D1094E97-9926-4A6E-A97A-E9AEDBDB5D1BQ40011916-E4925BAB-2213-4EAD-856A-B1E5EC916E4DQ42660162-FDE5FEC4-D30A-49CA-BF45-66BC96EF442DQ43547015-9334F16E-DDF4-432A-98EF-9CF66C7187DAQ43728275-41222CE0-6291-4A45-930D-170BEB4D43B2Q46102748-00972201-363B-4227-B1BC-180F99D1DE70Q46117208-458EEF8A-74AE-4771-9984-C95161886599Q47732599-7AA6D351-FB52-45C7-8642-E3B9E1D32397Q48715652-33F206D5-BF62-4C93-9382-684D04A51C4BQ51284070-DF80D2A9-E39A-408A-B823-2384BF30D500Q53635304-937E527B-18D1-4AAA-AF36-CFEA6C490E65Q56656130-04E1579B-5E8A-4C09-92E7-78A20094C784Q57911974-3B294D4B-C0A1-47C5-9DF2-C5B9AEAEF27D
P2860
Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Glycosylation and biological a ...... different culture conditions.
@ast
Glycosylation and biological a ...... different culture conditions.
@en
type
label
Glycosylation and biological a ...... different culture conditions.
@ast
Glycosylation and biological a ...... different culture conditions.
@en
prefLabel
Glycosylation and biological a ...... different culture conditions.
@ast
Glycosylation and biological a ...... different culture conditions.
@en
P2093
P356
P1433
P1476
Glycosylation and biological a ...... different culture conditions.
@en
P2093
P304
P356
10.1093/GLYCOB/5.8.813
P577
1995-12-01T00:00:00Z